tbuckley/cabot-search huggingface dataset:
Effect of erlotinib on platelet activation in patients with non-small cell lung cancer
Authors: K. Yamaguchi, S. Kanazawa, S. Sasada, T. Hirashima, F. Imamura, S. Nomura
Journal: Journal of Clinical Oncology (2009)

e22232 Background: Previously we reported that serum levels of soluble P-selectine and thromboxane (TX) B2 elevated in the patients with lung cancer treated with gefitinib and low dose aspirin improved skin eruption. We measured the serum levels of TXB2 in patients with NSCLC. Methods: Serial blood samples were withdrawn from each patient before and after the administration of erlotinib. TXB2 was measured by enzyme-linked immuno solvent assay. The kit was used according to the manufacturer's instructions. Results: The serum levels of TXB2 were elevated after treatment with erlotinib. Two cases developed skin lesion then treated with low dose aspirin. Skin lesions were better with improving itching without disease progression. Conclusions: We think that platelets activity, COX-1, COX-2 and PGI2 / TXA2 ratio are one of factor of anti-cancer and adverse effect for EGFR-TKI. And low dose aspirin may be useful for adverse effect of erlotinib and other EGFR-TKI. No significant financial relationships to disclose.
A Framework to Improve Surgeon Communication in High-Stakes Surgical Decisions
Authors: Lauren J. Taylor, Michael J. Nabozny, Nicole M. Steffens, Jennifer L. Tucholka, Karen J. Brasel, Sara K. Johnson, Amy Zelenski, Paul J. Rathouz, Qianqian Zhao, Kristine L. Kwekkeboom, Toby C. Campbell, Margaret L. Schwarze
Journal: JAMA Surgery (2017)

IMPORTANCE Although many older adults prefer to avoid burdensome interventions with limited ability to preserve their functional status, aggressive treatments, including surgery, are common near the end of life.Shared decision making is critical to achieve value-concordant treatment decisions and minimize unwanted care.However, communication in the acute inpatient setting is challenging.OBJECTIVE To evaluate the proof of concept of an intervention to teach surgeons to use the Best Case/Worst Case framework as a strategy to change surgeon communication and promote shared decision making during high-stakes surgical decisions. DESIGN, SETTING, AND PARTICIPANTSOur prospective pre-post study was conducted from June 2014 to August 2015, and data were analyzed using a mixed methods approach.The data were drawn from decision-making conversations between 32 older inpatients with an acute nonemergent surgical problem, 30 family members, and 25 surgeons at 1 tertiary care hospital in Madison, Wisconsin.INTERVENTIONS A 2-hour training session to teach each study-enrolled surgeon to use the Best Case/Worst Case communication framework. MAIN OUTCOMES AND MEASURESWe scored conversation transcripts using OPTION 5, an observer measure of shared decision making, and used qualitative content analysis to characterize patterns in conversation structure, description of outcomes, and deliberation over treatment alternatives. RESULTSThe study participants were patients aged 68 to 95 years (n = 32), 44% of whom had 5 or more comorbid conditions; family members of patients (n = 30); and surgeons (n = 17).The median OPTION 5 score improved from 41 preintervention (interquartile range, 26-66) to 74 after Best Case/Worst Case training (interquartile range, 60-81).Before training, surgeons described the patient's problem in conjunction with an operative solution, directed deliberation over options, listed discrete procedural risks, and did not integrate preferences into a treatment recommendation.After training, surgeons using Best Case/Worst Case clearly presented a choice between treatments, described a range of postoperative trajectories including functional decline, and involved patients and families in deliberation. CONCLUSIONS AND RELEVANCEUsing the Best Case/Worst Case framework changed surgeon communication by shifting the focus of decision-making conversations from an isolated surgical problem to a discussion about treatment alternatives and outcomes.This intervention can help surgeons structure challenging conversations to promote shared decision making in the acute setting.
Fc-Engineered NKG2D-IgG1 Fusion Proteins Target Leukemia Cells for Antibody-Dependent Cellular Cytotoxicity (ADCC) of NK Cells
Authors: Julia Hilpert, Katrin Baltz-Ghahremanpour, Benjamin J Schmiedel, Lothar Kanz, Gundram Jung, Ludger Grosse-Hovest, Helmut R. Salih
Journal: Blood (2011)
Dasatinib and Imatinib-Induced Reductions in BCR-ABL Transcript Levels Below 10% At 3 Months Are Associated with Improved Responses in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Analysis of Molecular Response Kinetics in the DASISION Trial
Authors: Andreas Hochhaus, Giuseppe Saglio, Charles Chuah, Carolina Pavlovsky, M. Brigid Bradley Garelick, Alexandre Lambert, Neil Shah
Journal: Blood (2011)
Proteomic Identification of TAL1/SCL-Interacting Proteins: ETO-2 and MTGR1 Interact with TAL1 in Erythroid Progenitors.
Authors: Ying Cai, Zhixiong Xu, Jingping Xie, Mark J. Koury, Scott W. Hiebert, Stephen J. Brandt
Journal: Blood (2004)
Education in wound care: Curricula for doctors and nurses, and experiences from the German wound healing society ICW
Authors: Karl-Christian Münter
Journal: Military Medical Research (2016)

The German wound healing society ICW (Initiative Chronische Wunden) started a training program for nurses in 2005. Certified by TÜV Rheinland the courses are regularly audited and the quality is ensured. More than 30000 nurses attended these courses in Germany. In three Chinese hospitals the ICW courses have been adopted. A close collaboration between Chinese and German experts in wound healing let to their further development and improvement. The article reviews the need for education in the treatment of chronic wounds for medical personnel - nurses and doctors. Experiences and perspectives are discussed.
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells
Authors: Michele Cea, Antonia Cagnetta, Yu-Tzu Tai, Mariateresa Fulciniti, Teru Hideshima, Dharminder Chauhan, Sun-Young Kong, Teresa Calimeri, Francesca Cottini, Jana Jakubikova, Alessio Nencioni, Marco Gobbi, Franco Patrone, Kenneth C. Anderson
Journal: Blood (2011)
Adoptive Transfer of Adenovirus Specific T-Cells in Children with Systemic Adenovirus Infection after Allogeneic Stem Cell Transplantation.
Authors: Tobias F. Feuchtinger, Susanne Matthes-Martin, Celine Richard, Thomas Lion, Klaus Hamprecht, Christina Peters, Michael Schumm, Robert Beck, Dietrich Niethammer, Rupert Handgretinger, Peter Lang
Journal: Blood (2005)
Gene Expression Profiling, Frozen and Paraffin Section Immunohistochemistry, and In Situ Hybridization for Determination of Monoclonality in Diffuse Large B-Cell Lymphoma.
Authors: Matthew W. Andres, Robin A. Roberts, Debbie J. Mustacich, Randy D. Gascoyne, Deborah A. Fuchs, Michael X. Wang, Rita M. Braziel, Wing C. Chan, Thomas M. Grogan, Lisa M. Rimsza
Journal: Blood (2004)
Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
Authors: A Chanan-Khan, M Egyed, T Robak, F A Martinelli de Oliveira, M A Echeveste, S Dolan, P Desjardins, J Z Blonski, J Mei, N Golany, J Zhang, J G Gribben
Journal: Leukemia (2017)

Randomized phase 3 study of lenalidomide versus chlorambucil as first-line therapy for older patients with chronic lymphocytic leukemia (the ORIGIN trial)
Clinico-Biological Characteristics and Prognosis of Non-M3 Acute Myeloid Leukemia with High Percentage of Myeloperoxisase Positive Blasts. Single Center Experience.
Authors: Pau Montesinos, Lorenzo Algarra, Jaime Sanz, Mari Luz Perez, Leonor Senent, Amparo Sempere, Federico Gomis, Susana Cantero, Jesus Martinez, Ignacio Lorenzo, Guillermo Sanz, Miguel Sanz
Journal: Blood (2006)
Strategies for Building Peer Surgical Coaching Relationships
Authors: Heather L. Beasley, Hala N. Ghousseini, Douglas A. Wiegmann, Nicole A. Brys, Sudha R. Pavuluri Quamme, Caprice C. Greenberg
Journal: JAMA Surgery (2017)

Peer surgical coaching is a promising approach for continuing professional development. However, scant guidance is available for surgeons seeking to develop peer-coaching skills. Executive coaching research suggests that effective coaches first establish a positive relationship with their coachees by aligning role and process expectations, establishing rapport, and cultivating mutual trust.To identify the strategies used by peer surgical coaches to develop effective peer-coaching relationships with their coachees.Drawing on executive coaching literature, a 3-part framework was developed to examine the strategies peer surgical coaches (n = 8) used to initially cultivate a relationship with their coachees (n = 11). Eleven introductory 1-hour meetings between coaching pairs participating in a statewide surgical coaching program were audiorecorded, transcribed, and coded on the basis of 3 relationship-building components. Once coded, thematic analysis was used to organize coded strategies into thematic categories and subcategories. Data were collected from October 10, 2014, to March 20, 2015. Data analysis took place from May 26, 2015, to July 20, 2016.Strategies and potentially counterproductive activities for building peer-coaching relationships in the surgical context to inform the future training of surgical coaches.Coaches used concrete strategies to align role and process expectations about the coaching process, to establish rapport, and to cultivate mutual trust with their coachees during introductory meetings. Potential coaching pitfalls are identified that could interfere with each of the 3 relationship-building components.Peer-nominated surgical coaches were provided with training on abstract concepts that underlie effective coaching practices in other fields. By identifying the strategies used by peer surgical coaches to operationalize these concepts, empirically based strategies to inform other surgical coaching programs are provided.
Long-term outcomes of radiotherapy for stage II testicular seminoma: The Mayo Clinic experience.
Authors: Christopher Leigh Hallemeier, Thomas Michael Pisansky, Brian Davis, Richard Choo
Journal: Journal of Clinical Oncology (2012)

327 Background: To report long-term outcomes of patients (pts) treated with radiotherapy (RT) for stage II testicular seminoma. Methods: Between 1974 and 2007, 52 pts received RT for clinical stage II testicular seminoma after radical inguinal orchiectomy; 3 pts were excluded due to no clinical follow-up. CT staging was used for 46 pts (94%). Estimates of overall (OS), relapse-free (RFS), and cause-specific (CSS) survival were determined using the Kaplan-Meier technique. Major cardiac event (MCE) was defined as myocardial infarction, coronary artery bypass grafting or stenting, or valve replacement. Second malignancy (SM) was defined as biopsy-confirmed malignancy occurring in the RT field. Results: The median pt age was 35 years. AJCC stage was IIA (n=23), IIB (n=7), IIC (n=15), and unknown (n=4). Three pts were treated for paraortic recurrence during surveillance for stage I seminoma. Four pts with IIB (n=1) or IIC (n=3) disease were treated with chemotherapy in addition to RT. The median total RT dose was 30.4 Gy. Prophylactic mediastinal/supraclavicular (MSCV) RT was given to 24 pts (49%). The median follow-up was 18 years (range 0.4-37). Estimates of OS, RFS, and CSS at 10 and 20 years were 94% and 81%, 79% and 70%, and 96% and 96%, respectively. OS, RFS, and CSS were not significantly different between stage groups. Recurrence occurred in 9 pts (18%); sites were MSCV (n=6), para-aortic (n=1), lung (n=1), and peritoneal cavity (n=1). Seven pts were successfully salvaged, while 2 pts died of seminoma. No patient with stage IIA/B that received prophylactic MSCV RT (n=11) experienced MSCV relapse. Among patients that did not receive prophylactic MSCV RT, 2 of 13 (15%) with stage IIA and 3 of 6 (50%) with stage IIB experienced MSCV relapse. MCE occurred in 10 pts (20%) at a median of 18 years (range 7-30) after RT. SM occurred in 5 pts (10%) at a median of 27 years (range 20-34) after RT. Conclusions: Infradiaphragmatic RT alone was associated with a significant risk of MSCV failure, particularly in patients with stage IIB disease, suggesting that chemotherapy may be the optimal treatment in this patient cohort. Most MCE and SM events occurred more than 20 years after RT, highlighting the importance of vigilant long-term follow-up.
Randomized Multicenter Phase 3 Trial of High-Dose Dexamethasone (dex) with or without Oblimersen Sodium (G3139; Bcl-2 antisense; Genasense) for Patients with Advanced Multiple Myeloma (MM).
Authors: Asher Alban Chanan-Khan, Ruben Niesvizky, Raymond J. Hohl, Todd M. Zimmerman, Neal P. Christiansen, Gary J. Schiller, Sandra Smith, Stanley Frankel
Journal: Blood (2004)
Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307
Authors: Gianantonio Rosti, Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, Luciano Levato, Giovanna Rege-Cambrin, Adele Capucci, Mario Tiribelli, Alfonso Zaccaria, Monica Bocchia, Fabio Stagno, Francesco Cavazzini, Giorgina Specchia, Bruno Martino, Michele Cedrone, Tamara Intermesoli, Francesca Palandri, Simona Soverini, Maria Teresa Bochicchio, Nicoletta Testoni, Giuliana Alimena, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, Michele Baccarani
Journal: Blood (2012)
Atrial Fibrillation and Ventricular Arrhythmias
Authors: Anne M. Gillis
Journal: Circulation (2017)

Sex-specific differences in the epidemiology, pathophysiology, clinical presentation, clinical treatment, and clinical outcomes of atrial fibrillation (AF), sustained ventricular arrhythmias, and sudden cardiac death are recognized. Sex hormones cause differences in cardiac electrophysiological parameters between men and women that may affect the risk for arrhythmias. The incidence and prevalence of AF is lower in women than in men. However, because women live longer and AF prevalence increases with age, the absolute number of women with AF exceeds that of men. Women with AF are more symptomatic, present with more atypical symptoms, and report worse quality of life in comparison with men. Female sex is an independent risk factor for death or stroke attributable to AF. Oral anticoagulation therapy for stroke prevention has similar efficacy for men and women, but older women treated with warfarin have a higher residual risk of stroke in comparison with men. Women with AF are less likely to receive rhythm control antiarrhythmic drug therapy, electric cardioversion, or catheter ablation in comparison with men. The incidence and prevalence of sustained ventricular arrhythmias and sudden cardiac death are lower in women than in men. Women receiving implantable cardioverter defibrillators for primary prevention of sudden cardiac death are less likely to experience sustained ventricular arrhythmias in comparison with men. In contrast, women receiving a cardiac resynchronization therapy implantable cardioverter defibrillator for the treatment of heart failure are more likely to benefit than men. Women are less likely to be referred for implantable cardioverter defibrillator therapy despite current guideline recommendations. Women are more likely to experience a significant complication related to implantable cardioverter defibrillator implantation in comparison with men. Whether sex differences in treatment decisions reflect patient preferences or treatment biases requires further study.
Involvement of Ets Factor Spi-B, E Protein E2-2, and Id2 in Waldenström's Macroglobulinemia.
Authors: Yangsheng Zhou, Xia Liu, Lian Xu, Zachary Hunter, Jenny Sun, Guang Yang, Bryan Ciccarelli, Christopher J Patterson, Lee A. Garrett-Sinha, Steven Treon
Journal: Blood (2009)
A nomogram to predict axillary response to neoadjuvant chemotherapy in clinically node positive breast patients.
Authors: Jose Vila, Roland L. Bassett, Elizabeth Ann Mittendorf, Isabelle Bedrosian, Simona Flora Shaitelman, Michael Charles Stauder, Mariana Chavez-Mac Gregor, Jennifer Keating Litton, Wei Tse Yang, Lei Huo, Henry Mark Kuerer, Kelly Hunt, Abigail Suzanne Caudle
Journal: Journal of Clinical Oncology (2015)

1034 Background: Many clinically node positive breast cancer patients receive neoadjuvant chemotherapy (NAC), with 40% converting to node negative. Recent trials suggest a potential role for limiting axillary surgery in these patients. This study was undertaken to develop a nomogram predicting the likelihood of axillary pathologic complete response (pCR) in biopsy-proven cN1 patients receiving NAC. Methods: Patients with cT1-4N1M0 disease who received NAC and underwent axillary lymph node dissection were identified. Patients received anthracycline- and/or taxane-based therapy with trastuzumab in HER2+ patients. Estrogen receptor (ER) was recorded as the percentage of cells staining positive. Univariate and multivariate logistic regression analyses were performed to determine factors predictive of nodal conversion. A nomogram to predict the likelihood of nodal pCR was constructed. Results: A total of 614 cN1 patients were included: 93 (15%) cT1, 367 (60%) cT2, 107 (17%) cT3, and 47 (8%) cT4. Imaging showed multifocal disease in 24% (146/614). Receptor status was ER+ in 75% (458/614), PR+ in 64% (394/612), and HER2+ in 20% (124/614). Axillary pCR was achieved in 37% (228/614). On univariate analysis, nuclear grade (OR 13.67 grade 3 vs. 1, p = < .001) and HER2+ status (OR 4.6, p < .0001) were predictive of nodal pCR. Significant negative factors included multifocality on imaging (OR 0.67, p = 0.045), lobular histology (OR 0.53, p < .0001), PR+ (OR 0.24, p < .0001), ER percentage as a continuous variable (OR 0.98, p < .0001) as well as ER+ categorized as > 1% staining (OR 0.29, p < .0001). Nomograms to predict nodal pCR were created using these variables in addition to the clinically significant factors of T stage and number of abnormal nodes on US ( < 4 vs. ≥ 4). The discrimination of the nomogram using ER positive ( > 1% staining) versus negative (AUC = 0.775) was improved using the percentage of ER staining (AUC = 0.789). Conclusions: Multifocality, histology, nuclear grade, ER, PR, and HER2 status predict the ability to achieve nodal pCR with NAC. A nomogram incorporating these factors predicts the likelihood of nodal pCR with NAC which may help guide decisions regarding surgical management of the axilla in these patients.
Donor Leukocyte Infusion after Stem Cell Transplantation in Patients with Juvenile Myelomonocytic Leukemia.
Authors: Ayami Yoshimi, Peter Bader, Susanne Matthes-Martin, Jan Starý, Thomas Klingebiel, Ulrich Duffner, Franco Locatelli, Tom Révész7, Charlotte M. Niemeyer
Journal: Blood (2004)
Randomized Clinical Trial Comparing Melphalan-Prednisone (MP), MP-Thalidomide (MP-THAL) and High-Dose Therapy Using Melphalan 100 MG/M2 (MEL100) for Newly Diagnosed Myeloma Patients Aged 65–75 Years. Interim Analysis of the IFM 99-06 Trial on 350 Patients.
Authors: Thierry Facon, Jean Yves Mary, Cyril Hulin, Lofti Benboubker, Michel Attal, Jean Luc Harousseau, Brigitte Pegourie, Marc Renaud, Gaelle Guillerm, Laurent Voillat, Carine Chaleteix, Jacques Troncy, Mathieu Monconduit, Philippe Casassus, Herve Maisonneuve, Veronique Dorvaux, Jerome Jaubert, Mamoun Dib, Chantal Doyen
Journal: Blood (2004)
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial
Authors: Esther N Oliva, Caterina Alati, Valeria Santini, Antonella Poloni, Alfredo Molteni, Pasquale Niscola, Flavia Salvi, Grazia Sanpaolo, Enrico Balleari, Ulrich Germing, Pierre Fenaux, Aspasia Stamatoullas, Giuseppe A Palumbo, Prassede Salutari, Stefana Impera, Paolo Avanzini, Agostino Cortelezzi, Anna Marina Liberati, Paola Carluccio, Francesco Buccisano, Maria Teresa Voso, Stefano Mancini, Austin Kulasekararaj, Fortunato Morabito, Monica Bocchia, Patrizia Cufari, Maria Antonietta Aloe Spiriti, Irene Santacaterina, Maria Grazia D'Errigo, Irene Bova, Gina Zini, Roberto Latagliata
Journal: The Lancet Haematology (2017)
Low Pre-Transplant Levels of 25-Hydroxyvitamin D3 Predict Relapse and Survival in Male but Not in Female Patients Undergoing Allogeneic Stem Cell Transplantation
Authors: Aleksandar Radujkovic, Axel Benner, Sascha Dietrich, Ute Hegenbart, Stefan O Schönland, Anthony D. Ho, Peter Dreger, Thomas Luft
Journal: Blood (2014)
Monosomy Karyotype in Acute Myeloid Leukemia Predicts Adverse Treatment Outcome with Low Complete Remission Rate and Worse Event-Free and Overall Survival, and Associates with High Functional Activity of Multidrug Resistance (MDR).
Authors: Hee Kyung Ahn, Dong Hwan (Dennis) Kim, Silvia Park, Jun Ho Jang, Kihyun Kim, Hee-Jin Kim, Sun-Hee Kim, Chul Won Jung
Journal: Blood (2009)
Germline Genetic Variation of ASXL1 and BIM Predicts Response to Imatinib and Identifies a Subset of High Sokal Risk Patients with the Greatest Risk of Treatment Failure and Disease Progression
Authors: Justine E Marum, Leanne Purins, David T Yeung, Wendy Tara Parker, David J Price, Paul PS Wang, Doris Stangl, Jasmina Geogievski, Bradley Chereda, Andreas Schreiber, Simon J Tuke, Timothy P. Hughes, Susan Branford
Journal: Blood (2015)
Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type <i>KRAS</i> metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Authors: S. Yuki, K. Shitara, M. Yoshida, D. Takahari, S. Utsunomiya, T. Yokota, Y. Sato, M. Tajika, K. Muro
Journal: Journal of Clinical Oncology (2011)

561 Background: Weekly cetuximab and irinotecan is a standard regimen in heavily pretreated patients with metastatic colorectal cancer (MCRC). The aim of this study was to prospectively evaluate the efficacy of combination chemotherapy with biweekly cetuximab and irinotecan in patients with pretreated MCRC harboring wild-type KRAS. Methods: Patients with wild- type KRAS MCRC that had progressed after chemotherapy with irinotecan, oxaliplatin, and fluoropyrimidine were included in this study. Cetuximab was administered at 500 mg/m 2 biweekly with irinotecan. The primary endpoint was response rate. The secondary endpoints included adverse events, progression-free survival, and overall survival. The pharmacokinetics of cetuximab was also evaluated in five patients. Results: From May, 2009 to February, 2010, a total of 31 patients were enrolled from five institutions. One patient was not eligible. Among the 30 assessable patients, ECOG PS was 0 in 12, 1 in 16, and 2 in two patients. The objective response rate was 30.0% (95% confidence interval [CI], 14.7-49.4), and the disease control rate (complete response, partial response, or stable disease) was 76.7% (95%CI, 61.4-92.3). The median progression-free survival was 5.3 months (95%CI, 3.4-7.3). Grade 3 skin toxicity was observed in 3 patients (10%), and treatment related death due to pneumonia occurred in one patient. Conclusions: The efficacy data are similar to those of standard dose of cetuximab plus irinotecan. Combination chemotherapy with biweekly cetuximab and irinotecan is effective for pretreated metastatic wild-type KRAS MCRC. No significant financial relationships to disclose.